Tru Hematology Test
Truvian Sciences, Inc. · Decision date Jan 16, 2026
What did the FDA decide?
FDA records K251249 as a 510(k) premarket notification, with a decision dated Jan 16, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Hematology
- Decision date
- Jan 16, 2026
Regulatory record facts
- Identifier
- K251249
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Truvian Sciences, Inc.
- Product code
- GKZ
- Decision code
- SESE
- Decision date
- Jan 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Counter, Differential Cell.
- Applicant
- Truvian Sciences, Inc.
- Product code
- GKZ
- FDA device class
- 2
FDA decision timeline
K251249 received
Application receipt date recorded by FDA.
K251249 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code GKZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Yumizen H550K260781 | HORIBA ABX SAS | 510(k) clearance | Sep 14, 2026 | FDA |
| Sysmex America, Inc. | 510(k) clearance | May 27, 2026 | FDA | |
Athelas HomeK243348 | Athelas, Inc. | 510(k) clearance | Feb 6, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Truvian Sciences, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- San Diego, CA
Sources and methodology
- Original FDA record: K251249
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

